Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins
- PMID: 12435703
- PMCID: PMC132793
- DOI: 10.1128/AAC.46.12.3971-3977.2002
Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins
Abstract
Site saturation mutagenesis of the 238 position in the SHV beta-lactamase was performed to identify the complete sequence requirements needed for the extended spectrum beta-lactamase (ESBL) phenotype. MICs (in micrograms per milliliter) in an isogenic background, Escherichia coli DH10B, demonstrated that the Gly238Ala mutation conferred the most resistance to penicillins and cephalosporins. The absolute increase in resistance was greatest against cefotaxime for the Gly238Ala mutant (0.06 to 8 micro g/ml). Except for the strain possessing the Gly238Pro beta-lactamase, ceftazidime MICs were also elevated. None of the mutant SHV beta-lactamases were expressed in as great an amount as the wild-type beta-lactamase. Kinetic analysis of the Gly238Ala mutant revealed that penicillin and cephalosporin substrates have a lower K(m) for the enzyme because of this mutation. Ampicillin and piperacillin MICs were inversely proportional to the side chain volume of the amino acid in cases larger than Ser, suggesting that steric considerations may be a primary requirement for penicillin resistance. Secondary structural effects explain increased resistance to oxyiminocephalosporins. Based upon this study, we anticipate that additional mutations of Gly238 in the SHV beta-lactamase will continue to be discovered with an ESBL (ceftazidime or cefotaxime resistant) phenotype.
Figures
Similar articles
-
Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.Antimicrob Agents Chemother. 1999 Aug;43(8):1881-7. doi: 10.1128/AAC.43.8.1881. Antimicrob Agents Chemother. 1999. PMID: 10428907 Free PMC article.
-
Role of Asp104 in the SHV beta-lactamase.Antimicrob Agents Chemother. 2006 Dec;50(12):4124-31. doi: 10.1128/AAC.00848-06. Epub 2006 Sep 18. Antimicrob Agents Chemother. 2006. PMID: 16982784 Free PMC article.
-
Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance.Biochim Biophys Acta. 2001 May 5;1547(1):37-50. doi: 10.1016/s0167-4838(01)00164-9. Biochim Biophys Acta. 2001. PMID: 11343789
-
Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.J Infect Dis. 1996 Jan;173(1):151-8. doi: 10.1093/infdis/173.1.151. J Infect Dis. 1996. PMID: 8537652
-
Extended-spectrum plasmid-mediated beta-lactamases.J Antimicrob Chemother. 1995 Jul;36 Suppl A:19-34. doi: 10.1093/jac/36.suppl_a.19. J Antimicrob Chemother. 1995. PMID: 8543494 Review.
Cited by
-
Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase Inhibitors.J Med Chem. 2015 Jul 23;58(14):5445-58. doi: 10.1021/acs.jmedchem.5b00341. Epub 2015 Jul 10. J Med Chem. 2015. PMID: 26102369 Free PMC article.
-
Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.Antimicrob Agents Chemother. 2007 Apr;51(4):1577-9. doi: 10.1128/AAC.01293-06. Epub 2007 Jan 12. Antimicrob Agents Chemother. 2007. PMID: 17220410 Free PMC article.
-
Predicting β-lactam resistance using whole genome sequencing in Klebsiella pneumoniae: the challenge of β-lactamase inhibitors.Diagn Microbiol Infect Dis. 2020 Nov;98(3):115149. doi: 10.1016/j.diagmicrobio.2020.115149. Epub 2020 Jul 25. Diagn Microbiol Infect Dis. 2020. PMID: 32858260 Free PMC article.
-
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.Diagn Microbiol Infect Dis. 2015 May;82(1):65-9. doi: 10.1016/j.diagmicrobio.2015.02.003. Epub 2015 Feb 14. Diagn Microbiol Infect Dis. 2015. PMID: 25737290 Free PMC article.
-
The continuing challenge of ESBLs.Curr Opin Pharmacol. 2007 Oct;7(5):459-69. doi: 10.1016/j.coph.2007.08.003. Epub 2007 Sep 17. Curr Opin Pharmacol. 2007. PMID: 17875405 Free PMC article. Review.
References
-
- Bradford, P. A., C. Urban, A. Jaiswal, N. Mariano, B. A. Rasmussen, S. J. Projan, J. J. Rahal, and K. Bush. 1995. SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob. Agents Chemother. 39:899-905. - PMC - PubMed
-
- Cantu III, C., W. Huang, and T. Palzkill. 1997. Cephalosporin substrate specificity determinants of TEM-1 β-lactamase. J. Biol. Chem. 272:29144-29150. - PubMed
-
- Cantu III, C., W. Huang, and T. Palzkill. 1996. Selection and characterization of amino acid substitutions at residues 237 to 240 of TEM-1 β-lactamase with altered substrate specificity for aztreonam and ceftazidime. J. Biol. Chem. 271:22538-22545. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
